Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

被引：0
|
作者：
Tu, Sanfang [1 ]
Zhou, Lijuan [1 ]
Huang, Rui [1 ]
Zhou, Xuan [1 ]
Yang, Jilong [1 ]
Li, Meifang [1 ]
Jin, Bo [1 ]
Wang, Langqi [1 ]
Zhuo, Yaqi [1 ]
Chen, Huifang [1 ]
Chang, Lung-Ji [2 ,3 ]
Li, Yuhua [1 ]
机构：
[1] Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Univ Elect Sci & Technol China, Sch Med, Chengdu, Peoples R China
[3] Geno Immue Med Inst, Shenzhen, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186622
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
    Cordoba, Shaun
    Onuoha, Shimobi
    Thomas, Simon
    Pignataro, Daniela Soriano
    Hough, Rachael
    Ghorashian, Sara
    Vora, Ajay
    Bonney, Denise
    Veys, Paul
    Rao, Kanchan
    Lucchini, Giovanna
    Chiesa, Robert
    Chu, Jan
    Clark, Liz
    Fung, Mei Mei
    Smith, Koval
    Peticone, Carlotta
    Al-Hajj, Muhammad
    Baldan, Vania
    Ferrari, Mathieu
    Srivastava, Saket
    Jha, Ram
    Vargas, Frederick Arce
    Duffy, Kevin
    Day, William
    Virgo, Paul
    Wheeler, Lucy
    Hancock, Jeremy
    Farzaneh, Farzin
    Domning, Sabine
    Zhang, Yiyun
    Khokhar, Nushmia Z.
    Peddareddigari, Vijay G. R.
    Wynn, Robert
    Pule, Martin
    Amrolia, Persis J.
    NATURE MEDICINE, 2021, 27 (10) : 1797 - +
  • [22] Targeting B Cell Precursor Acute Lymphoblastic Leukemia (ALL) with Chimeric Antigen Receptors (CARs) Specific for CD19 or CD22
    Orentas, Rimas J.
    Haso, Waleed
    Lee, Daniel W.
    Fry, Terry J.
    Wayne, Alan S.
    Mackall, Crystal L.
    MOLECULAR THERAPY, 2013, 21 : S125 - S125
  • [23] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
    Shaun Cordoba
    Shimobi Onuoha
    Simon Thomas
    Daniela Soriano Pignataro
    Rachael Hough
    Sara Ghorashian
    Ajay Vora
    Denise Bonney
    Paul Veys
    Kanchan Rao
    Giovanna Lucchini
    Robert Chiesa
    Jan Chu
    Liz Clark
    Mei Mei Fung
    Koval Smith
    Carlotta Peticone
    Muhammad Al-Hajj
    Vania Baldan
    Mathieu Ferrari
    Saket Srivastava
    Ram Jha
    Frederick Arce Vargas
    Kevin Duffy
    William Day
    Paul Virgo
    Lucy Wheeler
    Jeremy Hancock
    Farzin Farzaneh
    Sabine Domning
    Yiyun Zhang
    Nushmia Z. Khokhar
    Vijay G. R. Peddareddigari
    Robert Wynn
    Martin Pule
    Persis J. Amrolia
    Nature Medicine, 2021, 27 : 1797 - 1805
  • [24] Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis
    Nguyen, Thi Thuy
    Thanh Nhu, Nguyen
    Chen, Chia-Ling
    Lin, Chiou-Feng
    CANCER MEDICINE, 2023, 12 (18): : 18767 - 18785
  • [25] Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia
    Qiu, Yan
    Qian, Chong-Sheng
    Zhou, Hai-Xia
    Xu, Ming-Zhu
    Kang, Li-Qing
    Sun, Ai-Ning
    Wu, De-Pei
    Yu, Lei
    Xue, Shengli
    BLOOD, 2022, 140 : 10337 - 10338
  • [26] 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)
    Schultz, Liora M.
    Davis, Kara L.
    Baggott, Christina
    Chaudry, Christie
    Marcy, Anne Cunniffe
    Mavroukakis, Sharon
    Sahaf, Bita
    Kong, Katherine A.
    Muffly, Lori S.
    Kim, Stephen
    Meyer, Everett H.
    Fry, Terry J.
    Qin, Haiying
    Miklos, David B.
    Mackall, Crystal L.
    BLOOD, 2018, 132
  • [27] Correlative study on the efficacy and complications of CD19 chimeric antigen receptor T cells in the treatment of recurrent/refractory acute lymphoblastic leukemia
    Wen, W.
    Xiaoling, G.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1728 - 1728
  • [28] Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma
    Lai, Xun
    Gu, Xuezhong
    Tsao, Shih-Ting
    Zhang, Qin
    Liu, Yu-Chen
    Jiang Yaxian
    Yan, Li
    Chun, Jun
    Zhang, Rui
    Du, Yunyun
    Gao, Xiaoli
    Yang, Yingyu
    Qiu, Xiaolian
    Fang, Mingjing
    Wei, Song
    Chang, Lung-Ji
    BLOOD, 2017, 130
  • [29] A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia
    Yang, Junfang
    Li, Jianqiang
    Zhang, Xian
    Lv, Fanyong
    Guo, Xiaoling
    Wang, Qinglong
    Wang, Lin
    Chen, Dandan
    Zhou, Xiaosu
    Ren, Jinhai
    Lu, Peihua
    BLOOD, 2018, 132
  • [30] Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22
    Qin, Haiying
    Haso, Waleed
    Sang Minh Nguyen
    Fry, Terry J.
    BLOOD, 2015, 126 (23)
12345